Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antineoplastic agents targeting tyrosine kinases].

Tormod K Guren1, Thoralf Christoffersen, G Hege Thoresen

  • 1Farmakologisk institutt, Rikshospitalet, Universitetet i Oslo, Postboks 1057 Blindern, 0316 Oslo. t.k.guren@medisin.uio.no

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|November 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caregiver satisfaction with early integrated palliative care in oncology: secondary outcomes from the PALLiON cluster-RCT.

Frontiers in oncology·2026
Same author

Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity.

Cell reports. Medicine·2026
Same author

Pembrolizumab in advanced malignant peripheral nerve sheath tumors: a single-arm phase 2 trial.

NPJ precision oncology·2026
Same author

The SGLT2 inhibitor empagliflozin promotes increased fatty acid oxidation in skeletal muscle cells.

Naunyn-Schmiedeberg's archives of pharmacology·2025
Same author

Correction: Development of three-dimensional primary human myospheres as culture model of skeletal muscle cells for metabolic studies.

Frontiers in bioengineering and biotechnology·2025
Same author

Comment on 'Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoint Series' by Dajani et al.-The Authors' Reply.

Journal of cachexia, sarcopenia and muscle·2025

Tyrosine kinase inhibitors are a new class of cancer drugs targeting cellular signals. Some, like imatinib and trastuzumab, are effective treatments for specific cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinases are key regulators of cellular processes.
  • Targeting tyrosine kinases represents a novel approach in cancer therapy.
  • This review discusses agents targeting tyrosine kinases and their clinical applications.

Purpose of the Study:

  • To review the role of tyrosine kinases in cancer development.
  • To summarize the clinical data and applications of tyrosine kinase inhibitors.
  • To highlight established and emerging tyrosine kinase-targeted therapies.

Main Methods:

  • Literature review of recent scientific publications.
  • Inclusion of authors' personal clinical experience.
  • Analysis of clinical data for tyrosine kinase inhibitors.

Related Experiment Videos

Main Results:

  • Receptor and intracellular tyrosine kinases regulate proliferation, survival, and angiogenesis.
  • Imatinib is established for chronic myeloid leukemia and GIST.
  • Trastuzumab is used for breast cancer treatment.

Conclusions:

  • Tyrosine kinase inhibitors are a significant advancement in cancer treatment.
  • Targeted therapies like imatinib and trastuzumab demonstrate clinical efficacy.
  • Ongoing research into inhibitors of EGFR and other tyrosine kinases holds promise.